BioSpace News Archive

MolecuLight Inc.announces that it has received an expansion to its FDA 510 clearance for the MolecuLight i:X® imaging device’s ability to detect the location of elevated bacterial loads in wounds.

VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of 6,467,688 ordinary shares, including the sale to the underwriters of 752,688 ordinary shares sold pursuant to the partial exercise of the underwriters’ previously granted option to purchase additional ordinary shares.

Generian Pharmaceuticals, Inc. (“Generian”) and Mitobridge, Inc. (a wholly owned subsidiary of Astellas Pharma Inc. ) announced today that they have entered into a collaboration and exclusive license agreement to discover and develop novel small molecules for undruggable therapeutic targets by using a proprietary drug discovery platform for diseases that have limited treatment options.

AlzeCure Pharma AB today announced that the company has completed the clinical phase I study (multiple ascending dose, MAD) with repeated dosing of the drug candidate ACD856, with a focus on Alzheimer’s disease.

Molecular Targeting Technologies, Inc. (MTTI), announced that the first patient has been dosed in a clinical trial of EBTATE ( 177 Lu-DOTA-EB-TATE) for the treatment of patients with advanced, well differentiated neuroendocrine tumors.

STX-721 is a next-generation, highly selective Exon 20 mutant EGFR inhibitor designed for a best-in-class profile to overcome efficacy and toxicity limitations of currently available agents.

btt Corp. (btt), a medical technology company focused on the development of innovative devices and treatments for targeted heat shock protein induction, today announced that Oklahoma Rock Holdings, LLC (Oklahoma Rock) has completed an investment of $29.3 million.

Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development.

Hemodialysis Technology Company Diality Joins Innovative Kidney Care Campaign, Seeks to Improve Choice for Kidney Patients.